Viking Therapeutics is trading 4.1% down at $33.65 as investors position themselves ahead of the company’s Q2 2026 earnings report scheduled for July 29, 2026.
- Analysts expect the company to report zero revenue and a consensus loss of $1.21 per share for the quarter.
- Despite the pullback, the stock remains significantly below the average analyst price target of approximately $93.
- Market focus remains primarily on the progress of the VK2735 obesity trial rather than near-term financial results.